Anthrax Vaccine Market: By Product Type (Live Vaccine, and Sub Unit Vaccine), By Distribution Channel (Hospitals, Defense & Military Centers, and Others), and Geography

Anthrax Vaccine Market size was valued at USD 32.6 million in 2023 and is poised to grow at a 3.1% CAGR from 2024 to 2030. The anthrax vaccine market plays a crucial role in biodefense preparedness by offering protection against Bacillus anthracis, the bacterium causing anthrax. Anthrax can infect animals, particularly livestock Healthcare. As awareness of this risk grows, veterinarians and agricultural workers may require vaccination to protect themselves from accidental exposure. This could lead to increased demand in the veterinary sector. In addition, governments might invest in anthrax vaccines for broader public health preparedness, especially in regions with a higher risk of anthrax outbreaks due to environmental factors or the historical presence of the bacteria.

Moreover, the chilling possibility of anthrax being used as a bioweapon remains a significant concern. The infamous 2001 anthrax attacks in the US serve as a stark reminder, prompting governments around the world to prioritize biodefense preparedness, including stockpiling anthrax vaccines. As developing economies strengthen their public health and biodefense capabilities, the demand for anthrax vaccines is expected to rise in these regions, particularly in Asia Pacific. Also, continued government investment in biodefense programs, including vaccine research, development, and stockpiling, will be crucial for sustained market growth. However, the rigorous regulatory approval processes for vaccines can hinder the development and introduction of new anthrax vaccines.

Anthrax Vaccine Market Key Developments:

• In August 2023, the Lagos State Government was supported by the Federal Government with 50,000 vials of anthrax vaccines. Such initiatives are likely to drive the anthrax vaccine market growth.
• In July 2023, CYFENDUS, developed by Emergent BioSolutions Inc., got the approval from the U.S. FDA for post-exposure prophylaxis of disease in people between 18 years to 65 years identified with Bacillus anthracis infection. This vaccine is given in association with mandated antiviral drugs.
• In October 2022, US Biomedical Advanced Research and Development Authority (BARDA), nominated ICON plc as a part of the Administration for Strategic Preparedness and Response (ASPR) in the Department of Health and Human Services (HHS), to perform an anthrax vaccine clinical trial. The Anthrax vaccine AV7909 is presently under clinical trial evaluation.